Emerging Markets

Latest Headlines

Latest Headlines

Quintiles to offer guidance on navigating Asian drug projects

All the big CROs have made a practice of highlighting their full-service expertise in drug development in recent years. They've been styling themselves as consultants capable of guiding companies...

IIL developing firsts for vaccines in India

Chikungunya and Japanese encephalitis virus (JEV) are both mosquito-borne viruses, and Indian Immunologicals Limited is working on what could be the world's first chikungunya vaccine, as well as...

South Africa, Lonza partner on $210 million API facility

South Africa is partnering with Swiss contract manufacturer Lonza on a $210 million API plant in an investment that looks to cut government costs for treating HIV. Lonza will put up 500 million rand,...

Takeda opens new drug development center in China

Japan's Takeda is adding a new drug development center in Shanghai intended to complement the international clinical work now under way in Singapore and Cambridge, MA. Both of the existing...

Eisai renews focus on 'more attractive' Japan

Eisai is coming to believe that there's no place like home. The Japanese drugmaker says it's planning to pull back in the U.S. and refocus on East Asia, and not just because markets such as...

Providing insight into pharmaceutical manufacturing requires conversation

Take a look at a recent graph of health spending in the U.S., and you may see a visual metaphor for what faces drug manufacturing.

Dishman set to bail on API manufacturing in once-promising China

Dishman Pharmaceuticals & Chemicals ($DISHMAN.NS) appears poised to give up on manufacturing for now in China, which it believed held great promise when it first bought land there in 2005. But...

Owner arrested in Pakistani drug deaths cites Big Pharma conspiracy

A Big Pharma conspiracy and hospital error are possibly behind the deaths of dozens of heart patients, said the owner of a Pakistani drug manufacturer arrested in the case. His conspiracy theory...

Argentina fines GSK $93K for Synflorix vaccine trial

Argentina's government has fined GlaxoSmithKline ($GSK) $93,000 for its management of trials of the vaccine Synflorix in which 14 babies died. This case brings to light questions as to how big...

GE jumps in to biologics, vaccine manufacturing game

GE Healthcare is gearing up to give established pharma companies competition in emerging markets. The company announced this week it's teaming with German engineering firm M+W Group to help...
  • « first
  • ‹ previous
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • next ›
  • last »